Hamill John P.
SEC insider (Form 3/4/5 filer). CIK 0001716213. SrVP/CFO/Prin Fin & Acct Ofcr at Aprea Therapeutics, Inc. (APRE). 8 reported Form 4/5 transactions since Sep 2024; latest on Mar 31, 2026. Located in DOYLESTOWN, PA.
Companies Hamill John P. has filed insider reports for
- Aprea Therapeutics, Inc. (APRE): Officer, SrVP/CFO/Prin Fin & Acct Ofcr
Hamill John P.
CIK: 0001716213
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Aprea Therapeutics, Inc.
Discretionary Trading P&L
Holdings
Transaction History (8 total)
- Mar 31, 2026APRE
Aprea Therapeutics, Inc.
PurchaseDirectCommon Warrant
31K shares- - Mar 31, 2026APRE
Aprea Therapeutics, Inc.
PurchaseDirectPre-Funded Warrant
31K shares at avg. $0.81- - Mar 12, 2026APRE
Aprea Therapeutics, Inc.
AwardDirect10.1K shares- - Jan 30, 2026APRE
Aprea Therapeutics, Inc.
PurchaseDirect5.7K shares at avg. $0.89$5K - Dec 10, 2025APRE
Aprea Therapeutics, Inc.
PurchaseDirect5K shares at avg. $1.17$6K - Mar 27, 2025APRE
Aprea Therapeutics, Inc.
AwardDirect3.4K shares- - Oct 11, 2024APRE
Aprea Therapeutics, Inc.
PurchaseDirect50 shares at avg. $2.46$123.19 - Oct 10, 2024APRE
Aprea Therapeutics, Inc.
PurchaseDirect450 shares at avg. $2.61$1K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Mar 31, 2026 | APRE Aprea Therapeutics, Inc. | Purchase Common Warrant | 30,978 | - | - | Direct |
| Mar 31, 2026 | APRE Aprea Therapeutics, Inc. | Purchase Pre-Funded Warrant | 30,978 | $0.81 | - | Direct |
| Mar 12, 2026 | APRE Aprea Therapeutics, Inc. | Award | 10,095 | - | $0 | Direct |
| Jan 30, 2026 | APRE Aprea Therapeutics, Inc. | Purchase | 5,700 | $0.89 | $5,073 | Direct |
| Dec 10, 2025 | APRE Aprea Therapeutics, Inc. | Purchase | 5,000 | $1.17 | $5,825 | Direct |
| Mar 27, 2025 | APRE Aprea Therapeutics, Inc. | Award | 3,365 | - | - | Direct |
| Oct 11, 2024 | APRE Aprea Therapeutics, Inc. | Purchase | 50 | $2.46 | $123 | Direct |
| Oct 10, 2024 | APRE Aprea Therapeutics, Inc. | Purchase | 450 | $2.61 | $1,175 | Direct |
1-8 of 8 transactions